mTOR in health and in sickness (Q38590634)

4 September 2017

mTOR in health and in sickness (English)

1 reference

4 September 2017

Dritan Liko

1

1 reference

4 September 2017

Michael N Hall

series ordinal

2

1 reference

4 September 2017

22 September 2015

1 reference

Journal of Molecular Medicine

4 September 2017

1 reference

4 September 2017

93

1 reference

4 September 2017

10

1 reference

4 September 2017

1061-1073

1 reference

https://scigraph.springernature.com/pub.10.1007/s00109-015-1326-7

4 September 2017

0 references

cites work

FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Genetic ablation of PRAS40 improves glucose homeostasis via linking the AKT and mTOR pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Identification of Protor as a novel Rictor-binding component of mTOR complex-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Emerging common themes in regulation of PIKKs and PI3Ks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Conserved sequence motifs and the structure of the mTOR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

mTOR kinase structure, mechanism and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Molecular Basis of the Rapamycin Insensitivity of Target Of Rapamycin Complex 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Structure of the human mTOR complex I and its implications for rapamycin inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Stoichiometry and assembly of mTOR complexes revealed by single-molecule pulldown

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Metabolic stress controls mTORC1 lysosomal localization and dimerization by regulating the TTT-RUVBL1/2 complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Signal integration by mTORC1 coordinates nutrient input with biosynthetic output.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Nutrient signaling to mTOR and cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

mTOR signaling in growth control and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Target of rapamycin (TOR) in nutrient signaling and growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Molecular mechanisms of mTOR-mediated translational control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Making new contacts: the mTOR network in metabolism and signalling crosstalk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Rheb binds and regulates the mTOR kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Regulation of mTORC1 by amino acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Nutrient-sensing mechanisms and pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

The translational landscape of mTOR signalling steers cancer initiation and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Distinct perturbation of the translatome by the antidiabetic drug metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

A unifying model for mTORC1-mediated regulation of mRNA translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Translational coregulation of 5'TOP mRNAs by TIA-1 and TIAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Oxygen sufficiency controls TOP mRNA translation via the TSC-Rheb-mTOR pathway in a 4E-BP-independent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Reassessment of the role of TSC, mTORC1 and microRNAs in amino acids-meditated translational control of TOP mRNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

SKAR is a specific target of S6 kinase 1 in cell growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Cdc42 stimulates RNA splicing via the S6 kinase and a novel S6 kinase target, the nuclear cap-binding complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Activation of mTORC2 by association with the ribosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Conditional disruption of rictor demonstrates a direct requirement for mTORC2 in skin tumor development and continued growth of established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

mTOR in aging, metabolism, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Cognitive deficits in Tsc1+/- mice in the absence of cerebral lesions and seizures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

21 January 2018

The neurology of mTOR

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Autism spectrum disorder in the genetics clinic: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

The tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

FMRP S499 is phosphorylated independent of mTORC1-S6K1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Exaggerated translation causes synaptic and behavioural aberrations associated with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Coordinated regulation of protein synthesis and degradation by mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Activating mutations of TOR (target of rapamycin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

mLST8 Promotes mTOR-Mediated Tumor Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

MiR-424/503-mediated Rictor upregulation promotes tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

High glucose upregulation of early-onset Parkinson's disease protein DJ-1 integrates the PRAS40/TORC1 axis to mesangial cell hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Phosphorylation of PRAS40-Thr246 involved in renal lipid accumulation of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Proline-rich AKT substrate of 40-kDa (PRAS40) in the pathophysiology of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

PRR5 encodes a conserved proline-rich protein predominant in kidney: analysis of genomic organization, expression, and mutation status in breast and colorectal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

An evolving role for DEPTOR in tumor development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

A serine/threonine kinase gene defective in Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Tenets of PTEN tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Targeting mTOR dependency in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

mTOR, translation initiation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

mTORC1-mediated translational elongation limits intestinal tumour initiation and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Activation of a metabolic gene regulatory network downstream of mTOR complex 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Identification of Akt-independent regulation of hepatic lipogenesis by mammalian target of rapamycin (mTOR) complex 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Hepatic mTORC1 controls locomotor activity, body temperature, and lipid metabolism through FGF21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

mTORC1 directly phosphorylates and regulates human MAF1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Breakdown of the regulatory control of pyrimidine biosynthesis in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Accumulation of anchorage independent cells showing amplified genes (CAD) during the in vitro propagation of CHEF18 Chinese hamster cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Role of mTOR signaling in tumor cell motility, invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Rapamycin passes the torch: a new generation of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Rapalogs and mTOR inhibitors as anti-aging therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Pancreatic tumours escape from translational control through 4E-BP1 loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Rapamycin improves sociability in the BTBR T(+)Itpr3(tf)/J mouse model of autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

mTOR inhibition improves immune function in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Late-life rapamycin treatment reverses age-related heart dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Adverse events associated with mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Association of Gly972Arg polymorphism of IRS1 gene with type 2 diabetes mellitus in lean participants of a national health survey in Mexico: a candidate gene study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes: a meta-analysis of 27 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Identification of novel candidate genes for type 2 diabetes from a genome-wide association scan in the Old Order Amish: evidence for replication from diabetes-related quantitative traits and from independent populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

PI3K pathway alterations in cancer: variations on a theme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

mTOR signaling in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Identification of a novel splice variant of AML1b in ovarian cancer patients conferring loss of wild-type tumor suppressive functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Protein kinase C intervention: the state of play

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Mammalian target of rapamycin signaling in cardiac physiology and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Everolimus treatment of refractory epilepsy in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Mutations in DEPDC5 cause familial focal epilepsy with variable foci

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

DEPDC5 mutations in genetic focal epilepsies of childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Rapamycin activates autophagy in Hutchinson-Gilford progeria syndrome: implications for normal aging and age-dependent neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

mTOR signaling in polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Rapamycin nanoparticles target defective autophagy in muscular dystrophy to enhance both strength and cardiac function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Autophagy as a new therapeutic target in Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-015-1326-7

Mechanism of activation of protein kinase B by insulin and IGF-1

21 January 2018

1 reference

12 December 2020

Carbamoyl phosphate synthetase (glutamine-hydrolyzing): increased activity in cancer cells

1 reference

12 December 2020

Elucidating the role of DEPTOR in Alzheimer's disease

1 reference

12 December 2020

Phospho-PRAS40(Thr246) predicts trastuzumab response in patients with HER2-positive metastatic breast cancer

1 reference

12 December 2020

Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma

1 reference

12 December 2020

Inhibition of the immune response by rapamycin, a new antifungal antibiotic

1 reference

12 December 2020

Increased incidence of CAD gene amplification in tumorigenic rat lines as an indicator of genomic instability of neoplastic cells.

1 reference

12 December 2020

Rapamycin fed late in life extends lifespan in genetically heterogeneous mice

1 reference

12 December 2020

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

1 reference

12 December 2020

mTOR signaling in cellular and organismal energetics

1 reference

12 December 2020

Molecular scanning for mutations in the insulin receptor substrate-1 (IRS-1) gene in Mexican Americans with Type 2 diabetes mellitus

1 reference

12 December 2020

10.1007/S00109-015-1326-7

Identifiers

DOI

1 reference

Dimensions Publication ID

4 September 2017

1010658816

0 references

Fatcat ID

release_avfwrtahurgjnbocbzbixb7ncm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/avfwrtahurgjnbocbzbixb7ncm

24 November 2022

mapped directly with Wikidata item

1 reference